Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Twist Bioscience Corp — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.09 (market cap $44.49B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 4.4× Twist Bioscience Corp's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 66 Days and Twist Bioscience Corp for 27 Days on average.
| JEPQ | TWST | |
|---|---|---|
Market Cap | $44.49B | $10.08B |
Volume | 5,681,789 | 4,229,037 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $205.00 |
52-Week Low | $53.77 | $25.45 |
Typical Hold Time | 66 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.09, down 0.29% on the day, with a bullish technical signal driven by moving averages. The ETF maintains strong income generation through its covered-call strategy, with recent monthly dividends ranging from $0.57 to $0.70. Technical analysis shows support at $60-61 and resistance at $61-62, while oscillators remain neutral with RSI at 47.13.
JEPQ offers high monthly income potential with an estimated 11% yield, though its covered-call strategy limits upside appreciation. The ETF provides exposure to Nasdaq technology stocks with downside protection during volatility. Key risks include market correlation, income variability, and competition from other income ETFs. Institutional interest remains strong, with Envestnet recently increasing its position.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
